What does it cost to miss a deadline? For the company that makes the prescription painkiller Oxycontin, the answer could be more than $1 billion.
Dow Chemical is breaking off a significant portion of its chlorine operations in a deal valued...
A new report expects the market value for sepsis treatments to increase more than thirteen-fold...
Genentech, a member of the Roche Group, has announced plans to invest more than $125 million for...
Capsugel has announced that the company is investing more than $25 million to increase production capacity and deliver further quality enhancements for its vegetarian capsules.
The Supreme Court is taking up a challenge by industry groups and Republican-led states that want to roll back Obama administration environmental rules aimed at reducing power plant emissions of mercury and other hazardous air pollutants that contribute to respiratory illnesses, birth defects and developmental problems in children.
Merck & Co. says its board approved the repurchase of up to $10 billion more of its stock. The company said that amount will be added to the $1.7B remaining available for repurchase under a prior authorization.
Sun Pharma today, begins the integration of Ranbaxy's business following the successful closure of its merger. The integration, planned by Sun Pharma over many months, will focus on supporting strong growth.
Lycera Corp. today announced the achievement of a milestone under the Company's collaboration agreement with Merck, known as MSD outside the United States and Canada, triggering an undisclosed payment.
House Republicans quietly deepened recommended budget savings from the government's chief health care program for the poor by about $140 billion in recent weeks to offset part of the cost of higher payments to doctors who treat Medicare patients, according to officials familiar with the tradeoff.
BMS Acquires Exclusive License from Novo Nordisk for a Discovery Research Program Focused on Autoimmune DiseasesMarch 24, 2015 8:16 am | News | Comments
Bristol-Myers Squibb Company has signed an agreement with Novo Nordisk under which Bristol-Myers Squibb will acquire an exclusive global license to a discovery biologics research program focused on modulating the innate immune system as a therapy for autoimmune diseases.
The World Health Organization denied that politics swayed the decision to declare an international emergency over the spread of the Ebola virus last year, despite evidence senior staffers repeatedly discussed the diplomatic and economic fallout of such a move.
Takeda will use ImmunoGen's technology to develop cancer treatments. ImmunoGen will get $20 million upfront and is eligible for milestone payments potentially totaling up to $210 million, plus royalties on sales.
A recent report found the pharmaceutical industry increased its contribution to the global economy between 2006 and 2012.
Over nearly two decades, inventions and products licensed by academic institutions contributed more than $1 trillion to the U.S. economy, according to a recent report from the Biotechnology Industry Organization.
Pfizer and Eli Lilly announced today that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a $200 million upfront payment from Lilly in accordance with their collaboration agreement.
Evotec AG today announced that a definitive agreement for a major multi-component strategic alliance over the next five years has been signed with Sanofi. The transaction is expected to close on 31 March 2015.
Mergers and acquisitions in the pharmaceutical and biotechnology sectors set a record in 2014, according to a report by Evaluate Ltd.
Under the terms of the agreement, Daiichi Sankyo will pay a $200M up-front fee and subsequent sales-related payments of up to $625M. AstraZeneca will be responsible for manufacturing, will book all sales and will make sales-related commission payments to Daiichi Sankyo.
The analysis by New York-based GBI Research predicted the recent expiration of patents for several of the top current therapeutics--most notably Singulair, Advair and Symbicort--would allow generic versions to curb market growth.
Puerto Rico and AbbVie announced today the expansion of one of AbbVie’s existing sites in the island with an estimated investment of $30M. This expansion will add to Puerto Rico’s capabilities as a manufacturing destination for biotechnology and is expected to create up to 100 new jobs over the next two years.
Bipartisan House leaders are working on a $213 billion plan to permanently change how doctors are paid for treating Medicare patients, a costly problem that's vexed Congress for years, a document circulating among lawmakers showed Tuesday.
The analysis by research firm Global Data projects the market to rise from an overall value of $395 billion in 2014 to nearly $550 billion by 2020, an increase of almost 40 percent.
Galapagos NV has announced that Janssen Pharmaceutica NV and Galapagos have mutually agreed to terminate the inflammation alliance and option agreements between the companies.
Indiana's Medicaid program will receive more than $126,000 from a drug manufacturer that filed false claims to Medicaid and other federally funded health care programs.
Major drugmakers, the British government and a top Alzheimer's research charity are pooling more than $100 million to create a global fund to accelerate efforts to find a treatment or even a cure for the mind-robbing disease within a decade.
Valeant is raising its offer for Salix Pharmaceuticals to about $11.11 billion, heating up a bidding fight for the company.
GlaxoSmithKline has announced the completion of the disposal of half of its 12.4% shareholding in Aspen. Following settlement of the sale, GSK will hold 28.2 million ordinary shares in Aspen, representing approximately 6.2% of the issued share capital.
Berry Plastics Group, Inc. and Klöckner Pentaplast Group, announced that the companies recently entered into a marketing alliance to offer innovative form-fill seal packaging solutions, on a global basis to the food, consumer, pharmaceutical, and medical markets.
- Page 1